Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FDPS | P14324 | 4/20 | 0.45 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.37 |
| ▸ | ODC1 | P11926 | 2/20 | 0.33 |
| ▸ | NFKB1 | P19838 | 2/20 | 0.33 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 3/20 | 0.32 |
| ▸ | BLM | P54132 | 3/20 | 0.32 |
| ▸ | CA12 | O43570 | 2/20 | 0.32 |
| ▸ | CA1 | P00915 | 2/20 | 0.32 |
| ▸ | CA2 | P00918 | 2/20 | 0.32 |
| ▸ | CA3 | P07451 | 2/20 | 0.32 |
| ▸ | CA4 | P22748 | 2/20 | 0.32 |
| ▸ | CA6 | P23280 | 2/20 | 0.32 |
| ▸ | CA5A | P35218 | 2/20 | 0.32 |
| ▸ | CA7 | P43166 | 2/20 | 0.32 |
| ▸ | CA9 | Q16790 | 2/20 | 0.32 |
| ▸ | CA14 | Q9ULX7 | 2/20 | 0.32 |
| ▸ | CA5B | Q9Y2D0 | 2/20 | 0.32 |
| ▸ | DNM1 | Q05193 | 1/20 | 0.32 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10804336 | 0.75 | FDPS (0.38) | FDPSPDE3AODC1NFKB1LMNA | |
| SCHEMBL16731982 | 0.71 | — | — | |
| SCHEMBL9682307 | 0.70 | PAOX (0.39) | FDPSODC1NFKB1CYP2D6LMNA | |
| SCHEMBL4542992 | 0.68 | — | — | |
| SCHEMBL10949215 | 0.67 | — | — | |
| SCHEMBL1512913 | 0.67 | ODC1 (0.47) | FDPSPDE3AODC1NFKB1CYP2D6 | |
| SCHEMBL1512916 | 0.67 | ODC1 (0.47) | FDPSPDE3AODC1NFKB1CYP2D6 | |
| SCHEMBL28313049 | 0.66 | FDPS (0.52) | FDPSPDE3ANFKB1LMNABLM | |
| SCHEMBL16005248 | 0.66 | FDPS (0.52) | FDPSPDE3ANFKB1LMNABLM | |
| SCHEMBL6368202 | 0.66 | FDPS (0.52) | FDPSPDE3ANFKB1LMNABLM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 67 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024054198-A1 | REPRESSED ANG 1-7 IN COVID-19 IS INVERSELY ASSOCIATED WITH INFLAMMATION AND COAGULATION | UNIVERSITY OF VIRGINIA PATENT FOUNDATION (US) | 2024-03-14 | — | — | WO | disclosed |
| US-20230355553-A1 | COMPOSITIONS AND METHODS FOR TREATING AND/OR PREVENTING OCULAR DISORDERS | UNIVERSITY OF VIRGINIA PATENT FOUNDATION (US) | 2023-11-09 | — | — | US | disclosed |
| WO-2023081861-A1 | ENHANCED EXPRESSION VIA AUTOTRANSPORTERS | UNIVERSITY OF VIRGINIA PATENT FOUNDATION (US) | 2023-05-11 | — | — | WO | disclosed |
| US-20220401580-A1 | OPTIDICER CONSTRUCT FOR AGE-RELATED MACULAR DEGENERATION | UNIVERSITY OF VIRGINIA PATENT FOUNDATION (US) | 2022-12-22 | — | — | US | disclosed |
| US-20220347144-A1 | COMPOSITIONS AND METHODS FOR PREVENTING AND/OR REDUCING WEIGHT GAIN AND ASSOCIATED CONDITIONS | UNIVERSITY OF VIRGINIA PATENT FOUNDATION (US) | 2022-11-03 | — | — | US | disclosed |
| US-20220331417-A1 | MODIFIED VESICULAR STOMATITIS VIRUS GLYCOPROTEIN AND USES THEREOF FOR THE TREATMENT OF BRAIN TUMORS | Université Catholique de Louvain (BE) | 2022-10-20 | — | — | US | disclosed |
| CN-108885217-B | Use of receptor binding domains from bovine leukemia virus for diagnosis or treatment of cationic L-amino acid transporter-related diseases | 梅塔福拉生物系统公司 | 2022-10-18 | — | — | CN | disclosed |
| EP-4034153-A1 | MODIFIED VESICULAR STOMATITIS VIRUS GLYCOPROTEIN AND USES THEREOF FOR THE TREATMENT OF BRAIN TUMORS | Université catholique de Louvain (BE) | 2022-08-03 | — | — | EP | disclosed |
| US-20210393768-A1 | COMPOSITIONS AND METHODS FOR PREVENTING AND TREATING VIRUS INFECTION | UNIVERSITY OF VIRGINIA PATENT FOUNDATION (US) | 2021-12-23 | — | — | US | disclosed |
| CN-113508301-A | Use of ligands derived from porcine endogenous virus receptor binding domain type B in the diagnosis of SMVT-associated diseases | 梅塔福拉生物系统公司 | 2021-10-15 | — | — | CN | disclosed |
| EP-0700301-A4 | PEPTIDES AND COMPOUNDS THAT BIND TO ELAM-1 | AFFYMAX TECH NV (AN) | 1998-01-07 | — | — | EP | disclosed |
| US-5648458-A | Peptides and compounds that bind to ELAM-1 | AFFYMAX TECHNOLOGIES N.V. (AN) | 1997-07-15 | — | — | US | disclosed |
| US-5643873-A | ANTIINFLAMMATORY | AFFYMAX TECHNOLOGIES N.V. (AN) | 1997-07-01 | — | — | US | disclosed |
| US-5635597-A | POLYPEPTIDE WHICH SPECIFICALLY BINDS TO INTERLEUKIN-2 (IL-2) RECEPTOR SUBUNITS TO BLOCK BINDING BY INTERLEUKIN-2; IMMUNOLOGY | AFFYMAX TECHNOLOGIES, N.V. (AN) | 1997-06-03 | — | — | US | disclosed |
| EP-0759769-A1 | PEPTIDES AND COMPOUNDS THAT BIND SELECTINS INCLUDING ENDOTHELIUM LEUKOCYTE ADHESION MOLECULE 1 (ELAM-1) | AFFYMAX TECHNOLOGIES N.V. (AN) | 1997-03-05 | — | — | EP | disclosed |
| WO-1996039165-A1 | PEPTIDES AND COMPOUNDS THAT BIND TO THE IL-1 RECEPTOR | AFFYMAX TECHNOLOGIES N.V. (GB) | 1996-12-12 | — | — | WO | disclosed |
| EP-0700301-A1 | PEPTIDES AND COMPOUNDS THAT BIND TO ELAM-1 | AFFYMAX TECHNOLOGIES N.V. (AN) | 1996-03-13 | — | — | EP | disclosed |
| WO-1995031210-A1 | PEPTIDES AND COMPOUNDS THAT BIND SELECTINS INCLUDING ENDOTHELIUM LEUKOCYTE ADHESION MOLECULE 1 (ELAM-1) | AFFYMAX TECHNOLOGIES NV (AN) | 1995-11-23 | — | — | WO | disclosed |
| WO-1995020973-A1 | PEPTIDES AND COMPOUNDS THAT BIND TO THE IL-1 RECEPTOR | AFFYMAX TECHNOLOGIES N.V. (AN) | 1995-08-10 | — | — | WO | disclosed |
| WO-1994025043-A1 | PEPTIDES AND COMPOUNDS THAT BIND TO ELAM-1 | AFFYMAX TECHNOLOGIES N.V. (AN) | 1994-11-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210393768-A1 | COMPOSITIONS AND METHODS FOR PREVENTING AND TREATING VIRUS INFECTION | CD4, VMP1, VAC14 | FDPS 4143/4885PDE3A 3103/4885ODC1 3233/4885 |
| US-20230355553-A1 | COMPOSITIONS AND METHODS FOR TREATING AND/OR PREVENTING OCULAR DISORDERS | NLRP3, PYCARD, HTRA1 | FDPS 3557/4885PDE3A 259/4885ODC1 4426/4885 |
| US-20220401580-A1 | OPTIDICER CONSTRUCT FOR AGE-RELATED MACULAR DEGENERATION | RNASE1, AGO2, DCLRE1B | FDPS 2325/4885PDE3A 479/4885ODC1 68/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.